Florida hasn't had a CFO in months. Who will DeSantis pick, and why does it matter?
"Without a CFO in place, who in the hell is doing the business of the people?" asked former CFO Jimmy Patronis in a recent podcast. Patronis left the post on April 1 to replace former U.S. Rep. Matt Gaetz as Northwest Florida's member of Congress.
Susan Miller, who was chief of staff under Patronis, is currently in charge of the Department of Financial Services, but Gov. Ron DeSantis has not officially named her CFO, even on an interim basis. The last press release from the department was in May, according to its website.
The vacancy in a high-level cabinet position is unusual — the CFO is third in the line of succession for governor, after the lieutenant governor and attorney general.
Especially since Florida also currently has no lieutenant governor: Former Lt. Gov. Jeanette Nuñez left that role in February to be interim president of Florida International University, one of several DeSantis allies in leadership positions in Florida's higher education. (She's since been confirmed as president permanently.)
At the first Florida Cabinet meeting since Patronis' absence, every new regulation or rule change was approved unanimously by DeSantis, Attorney General (and former DeSantis chief of staff) James Uthmeier, and Agriculture Commissioner Wilton Simpson.
DeSantis had said he would appoint a temporary CFO by mid-May, after the scheduled end of the regular legislative session. But the session was extended due to a stalemate over budget talks between the House and Senate. A final budget was approved on June 17 and now awaits DeSantis' review. Now, a CFO choice could be forthcoming.
When a choice is made, it may bring more Republican drama.
DeSantis is said to favor a staunch loyalist for the position: Sen. Blaise Ingoglia, R-Spring Hill.
At the same time, Sen. Joe Gruters, R-Sarasota, last year announced his intent to run for the open seat in 2026. He's endorsed by President Donald Trump.
It could make for an awkward GOP primary since Ingoglia is expected to also file to run for the seat for a full term. And Ingoglia, if appointed to serve the rest of Patronis' term, technically would have the advantage of being the incumbent.
Here's what to know, and why it's important:
The Department of Financial Services is powerful, in charge of paying state vendors and overseeing insurance, financial regulators and fire investigations.
It was created in 2002 after the Florida Cabinet was overhauled in 1998 by combining the former offices of comptroller, treasurer, insurance commissioner, and fire marshal.
"My department serves consumers and taxpayers through its work in 13 different divisions and additional initiatives I set forth," Patronis once wrote for the DFS website. "A world of information and assistance is provided by the department on issues ranging from insurance education and assistance, fire prevention and safety, and even unclaimed cash and property.
"I have also established additional priorities to assist Floridians including fighting fraud, consumer protection and fiscal transparency."
The DFS is made of the following divisions, each one with a direct impact on Floridians:
Accounting and Auditing
Consumer Services
Criminal Investigations
Funeral, Cemetery, and Consumer Services
Insurance Agent and Agency Services
Office of Financial Regulation
Office of Insurance Regulation
Rehabilitation and Liquidation
Risk Management
Treasury
State Fire Marshal
Unclaimed Property
Workers' Compensation
State Sen. Joe Gruters, R-Sarasota, is a long-time Trump ally who has support from Patronis and some influential Trump backers.
DeSantis will be making the interim appointment, however, and the two men have had a contentious relationship.
'I don't know where the Governor's going to go with the CFO seat, although I'm pushing hard and I'd like to have it now because I think it'd be better for Florida,' Gruters told reporters in December. He announced his bid for the CFO position in June 2024.
Gruters, 47, is a Tampa native with a bachelors' degree from Florida State University and an MBA from the University of South Florida. Previously a CPA for Robinson, Gruters & Roberts PA CPA LLC in Venice, he worked for multiple campaigns and became the chair of the Sarasota Republican Party.
Gruters was an early Trump supporter and one of the few GOP leaders who got behind him in 2012. He became Florida co-chair of Trump's 2016 campaign.
He won election as a House member in 2016 and moved to the Florida Senate two years later. He was reelected to the Senate in 2022.
In 2019 he was elected chair of the Republican Party of Florida and reelected in 2021. In 2023, Trump appointed Gruters to manage the Patriot Legal Defense Fund, his tax-exempt legal defense expense fund. Trump announced in April he was appointing Gruters to vice chair of the White House Homeland Security Council.
Gruters and DeSantis clashed back when Gruters was the state GOP chair over Gruters' pay and his organization of a fundraiser for the party. It didn't help when Gruters sided with Trump during DeSantis' campaign for the Republican presidential nomination, and later criticized the governor for spending taxpayer funds to attack an amendment that would have legalized recreational marijuana; Gruters supported the amendment.
Gruters is married to Sydney Gruters and they have three children. Sydney Gruters was appointed by Trump in his first term to serve as the state director for Florida and the U.S. Virgin Islands for the U.S. Department of Agriculture. After that she worked as district director for U.S. Rep. Greg Steube before being hired as executive director of the New College Foundation during DeSantis' experiment in revamping the liberal arts college along more conservative lines.
State Sen. Blaise Ingoglia, R-Spring Hill, is a Queens, New York, native who moved to Florida in 1996 to start a mortgage company and homebuilding company. He became politically active, his bio says, when property taxes skyrocketed, founding "Government Gone Wild" and producing seminars and videos over governmental wastefulness.
The 54-year-old was elected chair of the Hernando County Republican Executive Committee in 2009, and then was elected vice-chair of the Republican Party of Florida in 2011.
In 2014, he was elected to the Florida House of Representatives and was later chosen chair of the Republican Party of Florida. He was reelected as state chair in 2017. Ingoglia ran for the Florida Senate in 2022 with DeSantis' endorsement and won.
As a close ally of DeSantis, described as the governor's "conservative pitbull in the Florida Senate,' Ingoglia has criticized legislative leaders during a rift with the governor over immigration laws. He's sponsored bills in line with DeSantis' agenda, including lowering property taxes and imposing term limits on local officials.
Ingoglia has been an official campaign spokesperson for both Trump and DeSantis.
This story includes previous reporting by Gray Rohrer of the USA TODAY Network – Florida Capital Bureau.
This article originally appeared on Tallahassee Democrat: Florida Chief Financial Officer pick may come down to loyalties
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
US securities regulator announces AI task force
(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision
